A Georgia woman has filed a negligence lawsuit against Kaiser Permanente, alleging that the potential mislabeling of a pathology specimen led to a false cancer diagnosis, an unnecessary hysterectomy, and months of emotional and physical trauma. The case underscores how a single breakdown in specimen identification can have life-altering consequences for patients and significant legal ramifications for healthcare organizations.
According to the lawsuit, Cassandra Barksdale underwent a biopsy in March 2025 after seeking treatment for heavy bleeding and uterine fibroids. She was subsequently told she had an aggressive form of endometrial cancer and underwent a full hysterectomy on May 15, 2025. She was also told to expect instructions regarding chemotherapy.
Months later, however, DNA analysis reportedly determined that the cancerous tissue sample belonged to a different patient. The lawsuit alleges that another patient's pathology specimen had been mistakenly labeled as Barksdale's, resulting in treatment decisions based on an incorrect diagnosis. It remains unclear where in the testing or specimen-handling process the alleged mix-up occurred.
Case highlights risk of specimen identification errors
Concerns about specimen identification errors are not new. More than a decade ago, The Dark Report highlighted a collaborative quality improvement initiative involving nine Pennsylvania hospitals that reduced laboratory specimen labeling errors by 37% after standardizing collection and identification practices. That project demonstrated that while specimen misidentification is relatively uncommon, consistent labeling protocols and process improvements can significantly reduce the risk of patient harm—a lesson reinforced by the allegations in the current lawsuit.
For clinical laboratories and pathology practices, the case serves as a stark reminder of the importance of specimen identification protocols and chain-of-custody safeguards throughout the pathology workflow. Although specimen misidentification is considered uncommon, even a single labeling error can cascade into catastrophic clinical decisions when pathology results guide surgery or cancer treatment.
Kaiser Permanente said in a statement that Barksdale "should not have experienced this" and stated that the organization has highly trained staff and established processes designed to prevent such errors. The health system said it implemented additional measures after the incident to ensure it could not happen again and is working toward a fair resolution.
The lawsuit seeks unspecified damages. Because of patient privacy laws, no information has been released about the patient whose tissue sample was allegedly mislabeled or whether that patient's care was also affected.
